Hrnciar J
Interná klinika A, Nemocnica F.D. Roosewelta, Banská Bystrica, Slovenská republika.
Vnitr Lek. 2002 Jan;48(1):38-44.
In the seventies thyrotoxic heart accounted for 3% of all hospitalized cardiac patients and was found on average in 30% of all cases of hyperthyroidism. It presented most frequently by tachyfibrillation and resistant cardiac decompensation. It affected men four times as frequently as women. The incidence correlated with age, toxic nodose goitre, but its development did not correlate with concurrent thyrotoxic rhizomyelic myopathy nor with the extent of deviation of thyroid laboratory parameters (T4, T3, indexes FT4). At present the incidence of thyrotoxic heart declined due to early detection and more adequate diagnosis and treatment of hyperthyroidism, as well as due to the decline of oligosymptomatic toxic nodose goitres even in old age due to preventive iodization of table salt. However, there was an increase of hyperthyroidism induced by amiodarone and other iodine preparations (X-ray contrast materials) associated with primary heart disease and arrhythmias. (Up to 2% of amiodarone treated patients). The ratio of so-called real subclinical thyrotoxicoses in the development of thyrotoxic heart is negligible. Isolated reduction of TSH in hospital screening is a frequent finding but is conditioned most frequently by: a) the 1st stage of the low thyroxin syndrome, b) the 1st stage of subacute thyroiditis, c) the influence of various drugs (iodine preparations, overdosage of T4 substitution, pharmacotherapy with glucocorticoids, dopamine etc.), d) methodical artefacts, e) natural pulsed secretion of TSH etc. Hospital screening of hyperthyroidism and thyrotoxic heart even in older people above 60 years by T4 and/or TSH (2nd generation equipment) is not effective because it is detected in 20% of current hospital admissions and in 60% of those admitted to intensive care unitpathologic values of T4 and/or TSH most frequently without non-thyroid causes (stages of the low thyroxin syndrome) are recorded. This hospital screening has a satisfactory sensitivity but low specificity and in a large number of people calls for further diagnostic steps. Therefore it is more suitable only after clinical examination of the patient to confirm suspected hyperthyroidism to examine FT4 and TSH (IRMA 3rd generation) or possibly supplement FT3 and other aimed tests.
在20世纪70年代,甲状腺毒症性心脏病占所有住院心脏病患者的3%,在所有甲状腺功能亢进病例中平均占30%。其最常见的表现是快速性房颤和难治性心脏代偿失调。男性受影响的频率是女性的四倍。发病率与年龄、毒性结节性甲状腺肿相关,但其发展与并发的甲状腺毒症性脊髓性肌病以及甲状腺实验室参数(T4、T3、游离甲状腺素指数)的偏离程度无关。目前,由于甲状腺功能亢进的早期发现、更充分的诊断和治疗,以及由于食盐预防性碘化,即使在老年,无症状毒性结节性甲状腺肿的发病率下降,甲状腺毒症性心脏病的发病率也有所下降。然而,胺碘酮和其他碘制剂(X线造影剂)引起的甲状腺功能亢进有所增加,且与原发性心脏病和心律失常有关(高达2%接受胺碘酮治疗的患者)。在甲状腺毒症性心脏病的发生中,所谓真正的亚临床甲状腺毒症的比例可忽略不计。在医院筛查中促甲状腺激素单独降低是常见发现,但最常见的原因是:a)低甲状腺素综合征第一阶段,b)亚急性甲状腺炎第一阶段,c)各种药物的影响(碘制剂、T4替代过量、糖皮质激素、多巴胺等药物治疗),d)方法学假象,e)促甲状腺激素的自然脉冲分泌等。即使对60岁以上的老年人,通过T4和/或促甲状腺激素(第二代设备)对甲状腺功能亢进和甲状腺毒症性心脏病进行医院筛查也无效,因为在当前住院患者中有20%检测到T4和/或促甲状腺激素的病理值,在重症监护病房入院患者中有60%检测到,且最常见的是无非甲状腺原因(低甲状腺素综合征各阶段)。这种医院筛查具有令人满意的敏感性,但特异性低,在大量人群中需要进一步的诊断步骤。因此,只有在对患者进行临床检查以确认疑似甲状腺功能亢进后,检查游离甲状腺素和促甲状腺激素(第三代免疫放射测定法)或可能补充游离三碘甲状腺原氨酸和其他针对性检查才更合适。